ArticleJournal of the American Chemical Society2026
Molecular Dynamics-Guided Design and Chemoproteomic Profiling of Covalent Kinase Activity Probes.
Article in Journal of the American Chemical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
15 authors.
Funding
Abstract
Covalent small molecule probes can be powerful tools to interrogate protein activity state in native cellular environments. The design of familywide activity probes requires an understanding of the molecular sources of conserved and target-specific small molecule targeting across protein family members. Here, we developed and applied a multifaceted docking and molecular dynamics (MD) simulation pipeline to design cell-permeable covalent kinase activity probes from a set of hinge-binding pharmacophores. This computationally-guided approach yielded a series of cell-active indazole sulfonylfluorides that target a conserved catalytic lysine in active protein kinases. Chemoproteomic profiling of a lead probe, K60P, confirmed engagement of more than 100 unique native kinases across several cancer cell lines. Competitive profiling identified kinases as the predominant class of specific targets for K60P but also highlighted significant nonkinase targets for K60P and the established covalent kinase probe, XO44, underscoring the utility of native kinase profiling in situ to identify relevant targets of small molecule kinase inhibitors in cells. Dose-, time- and site-specific proteomic mapping with a known target kinase, ABL1, coupled with a Bayesian Metropolis Monte Carlo (BMMC) kinetic modeling method showed that key descriptors of covalent probe efficiency could be predicted with straightforward dose- and time-dependent covalent engagement studies and highlighted
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.